In the world of science and discovery, change is constant, driven by continuous advancements and new insights. As the pace of medical advancements and scientific breakthroughs accelerates, the tools researchers use must reflect this.

IonOpticks’ mission has always been simple, develop technologies that push the boundaries of scientific discovery by providing researchers with the very best tools available. Existing talent across many departments have focused on this mission, in turn enabling thousands of researchers globally to unlock the full potential of their mass spectrometry instruments. And according to Dr Jarrod Sandow, Chief Product Officer at IonOpticks, there’s more innovation to come.

IonOpticks’ recent partnership with Nordic Private Equity firm Adelis has been extremely positive, bringing significant benefits to both existing and new customers. While the company has always served a global customer base, collaborating with a Nordic partner has provided greater insights into international markets while expanding the overall perspective.

“These brilliant minds in proteomics, business development, and brand building have invigorated the team and enhanced the company’s capabilities,” Jarrod explains.

“IonOpticks’ Board has expanded to include Dr. Peter Wrighton-Smith and Mårten Winge, whose insights have already proven invaluable to the company. The addition of Adelis’ representatives, Sibel Arnes and Rasmus Molander, both of whom bring a wealth of industry knowledge, has been instrumental. Having these industry heavyweights supporting the company and championing its vision, provides a significant advantage.”

Through an expanded Board of Directors and advisors, this partnership has also widened the company’s network. These leaders not only share a belief in IonOpticks’ mission but actively introduce the company to their networks, amplifying the impact of its work. As more people recognise the value of the company’s solutions, the global community of ambassadors and users continues to grow, fuelled in part by the power of word-of-mouth, which has been a huge contributor to its success to date.

This partnership also sets the stage for expanding global operations, enabling IonOpticks to build larger teams both within and beyond Australia which Jarrod believes is the next step in the company’s growth:

“As our international presence grows, the ability to build teams in regions with greater access to diverse perspectives expands, helping to overcome the isolation often felt in Australia. By tapping into this talent, the company can continue to develop innovative solutions that address the evolving challenges faced by researchers.”

IonOpticks’ growth to date has been a collaborative effort, uniting teams across R&D, production, marketing, and operations. The team is tight-knit, driven by a shared goal: delivering the best possible solutions for researchers. Now, as the next steps in the evolution are taken, Jarrod maintains the focus is on expanding this team on a global scale.

About Jarrod Sandow

Dr. Jarrod Sandow is not just the CPO at IonOpticks—he’s a driving force in the proteomics field. His dedication to innovation is shaping the future of how we understand human health. Leading a team of brilliant R&D scientists, Jarrod is focused on creating solutions that empower researchers and clinicians to dig deeper into their samples and fast-track discoveries in biology and medicine.

With a career spanning over 15 years in life sciences, Jarrod’s expertise has been crucial in delivering technologies that serve the global proteomics community. Before co-founding IonOpticks, he made significant strides as a senior researcher at the Walter and Eliza Hall Institute, working on a vast array of biomedical projects. He’s the kind of guy who’s as passionate about the minute details of product development as he is about the big picture of human health.